Could a safer dose after transplant help blood cancer patients recover with fewer infections?
NCT ID NCT06001385
Summary
This study is testing if using a lower dose of a standard drug (cyclophosphamide) given after a stem cell transplant can reduce serious infections in the first 100 days. The trial aims to see if this lower dose is just as good at preventing graft-versus-host disease, a common and serious transplant complication. It involves 313 adults with various blood cancers who are receiving stem cells from a partially matched, unrelated donor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Barnes Jewish Hospital / Washington University
St Louis, Missouri, 63110, United States
-
City of Hope
Duarte, California, 91010, United States
-
Colorado Blood Cancer Institute at Presbyterian St. Luke's
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Greenbaum Cancer Center University of Maryland
Baltimore, Maryland, 21201, United States
-
Honor Health
Scottsdale, Arizona, 85258, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Memorial Sloan Kettering Cancer Center - Adults
New York, New York, 10065, United States
-
Methodist Hospital San Antonio
San Antonio, Texas, 78229, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State Medical Center
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
St. David's South Austin Medical Center
Austin, Texas, 78704, United States
-
Stanford University
Stanford, California, 94305, United States
-
The Center for Bone Marrow Transplantation at Geisinger
Danville, Pennsylvania, 17822, United States
-
TriStar Centennial
Nashville, Tennessee, 37203, United States
-
Tufts University
Boston, Massachusetts, 02155, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Miami Sylvester Cancer Center
Miami, Florida, 33136, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.